Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
MWN-AI** Summary
In a recent interview, Exousia Bio, Inc. (OTCPINK: LMMY) spotlighted Dr. Marvin Hausman, an esteemed immunologist and urological surgeon, who brings over 50 years of drug development experience to the company. As Exousia Bio transitions from LAMY, it aims to lead in exosome-based cancer therapies, and Dr. Hausman's expertise significantly strengthens its mission to combat serious diseases, particularly cancer.
Dr. Hausman has an impressive background with contributions to major pharmaceutical firms, including Bristol-Myers Squibb and Medco Research (now Pfizer), where he was instrumental in securing six New Drug Applications (NDAs) and developing Wellbutrin, a leading antidepressant. His career reflects a successful integration of medicine and business, and he aspires to leave a powerful legacy in cancer research through his work with Exousia Bio.
In the interview, Hausman emphasized the transformative potential of exosomes, describing them as the body's communication system that delivers genetic materials between cells. His vision for Exousia Bio focuses on utilizing these smallest extracellular vesicles to target and treat aggressive cancers such as glioblastoma and small cell lung cancer. He sees exosomes not only as a future cornerstone of cancer therapy but also as a promising avenue for treating a range of viral infections.
Exousia Bio utilizes proprietary technologies to develop customized mammalian and plant-derived exosomes capable of selectively targeting cancer stem cells, the main drivers of cancer recurrence and metastasis. As the company continues to innovate in the biotechnology landscape, Dr. Hausman's insights and leadership are poised to propel its commitment to addressing significant unmet medical needs in oncology and beyond. For more details, the full interview is available at: https://youtu.be/XnfMHqBwBoI.
MWN-AI** Analysis
In light of the recent interview with Dr. Marvin Hausman, who brings over 50 years of experience in drug development to Exousia Bio, Inc. (OTCPINK: LMMY), investors should note the potential this company holds in the biotechnology sector, particularly in exosome-based cancer therapy. Dr. Hausman's background with major pharmaceutical firms underscores a strong grounding in both medical science and business, and his insights into exosome technology could position Exousia Bio as a frontrunner in the industry.
Exosomes are the subject of renewed interest due to their ability to facilitate cell communication, which could revolutionize treatment methodologies for aggressive cancers like glioblastoma and small cell lung cancer. This novel approach not only aims to treat cancer more effectively but also targets the cancer stem cells responsible for recurrence, addressing a significant gap in current therapeutic strategies. As Dr. Hausman iterates, the commitment to harnessing exosomes could be pivotal for Exousia's growth trajectory.
Investors should closely monitor developments related to Exousia Bio's proprietary exosome technology, as advancements here could lead to groundbreaking treatments and potentially lucrative partnerships within the healthcare ecosystem. However, it is vital to acknowledge the inherent risks associated with biopharmaceutical development. The company's current status as an OTC entity means investors should approach with caution, considering the volatility often linked with small-cap stocks and the long timelines typical in drug development.
Given Dr. Hausman’s track record and the promising nature of exosome technology, investors who back Exousia Bio may find themselves well-positioned to capitalize on future advancements. Conduct thorough due diligence, but consider looking for entry points into this innovative biotech player as it seeks to carve out its niche in the ever-evolving cancer treatment landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases.
ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research and development, Dr. Hausman has contributed to groundbreaking work at leading pharmaceutical organizations including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, and Medco Research (now part of Pfizer). His insights bring unparalleled expertise to the Company’s strategic initiatives and underscore its commitment to advancing innovation in healthcare.
In the discussion, Hausman highlighted his career and where he hopes to take Exousia Bio, "I have been privileged to play a role in successfully obtaining six NDAs for major pharmaceutical companies. At Medco, one of the drugs we developed was Wellbutrin, which has become one of the world’s leading antidepressants. What I truly value is the ability to bridge medicine and business, and my goal is to leave a lasting legacy in the fight against cancer, the field where my work first began.”
In terms of where he thinks Exo Bio can thrive, he stated, "Exosomes represent the future of healthcare. As the smallest extracellular vesicles, they serve as the body’s communication system - carrying mRNA, proteins, and amino acids between cells, whether cancerous or healthy. I am fascinated by their potential and aspire to leave a legacy in healthcare with Exousia Bio by advancing the use of exosomes in treating devastating cancers such as glioblastoma, and in pioneering approaches like those recently announced for small cell lung cancer."
For the full interview, please visit: https://youtu.be/XnfMHqBwBoI
About LAMY (to become) Exousia Bio, Inc.
Exousia Bio, Inc., a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. The same platform technology also holds promise for treating a broad spectrum of viral infections.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. LAMY's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of LAMY, and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects, as well as changes in products and competition.
CONTACT:
Exousia Bio, Inc.
www.exousiabio.com
X: @ExousiaBio
Investor Relations
ir@exousiabio.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8189ad48-2a0e-422a-b471-1920f6d71b76
FAQ**
How does Dr. Hausman's extensive experience contribute to Exousia Bio, Inc. (L A M Y, Inc. LMMY)'s strategy in advancing exosome-based therapies for cancer treatment?
What specific advancements does Exousia Bio, Inc. (L A M Y, Inc. LMMY) hope to achieve in using exosomes for targeting cancer stem cells in diseases like glioblastoma and pancreatic cancer?
Given the risks mentioned in the safe harbor statement, what measures is Exousia Bio, Inc. (L A M Y, Inc. LMMY) taking to mitigate potential uncertainties in their drug development pipeline?
Can Dr. Hausman elaborate on how the proprietary technologies for exosome development at Exousia Bio, Inc. (L A M Y, Inc. LMMY) differentiate the company from its competitors in the biotechnology sector?
**MWN-AI FAQ is based on asking OpenAI questions about L A M Y, Inc. (OTC: LMMY).
NASDAQ: LMMY
LMMY Trading
0.0% G/L:
$0.31 Last:
1,876 Volume:
$0.31 Open:
